Nanogen Inc., of San Diego, was issued five additional U.S. patents: No. 6,258,606, ¿Multiplexed Active Biologic Array¿; No. 6,287,517, ¿Laminated Assembly for Active Bioelectronic Devices¿; No. 6,284,117, ¿Apparatus and Method for Removing Small Molecules and Ions from Low Volume Biological Samples¿; No. 6,280,590, ¿Channel-Less Separation of Bioparticles on a Bioelectronic Chip by Dielectrophoresis¿; and No. 6,254,827, ¿Methods for Fabricating Multi-Component Devices for Molecular Biological Analysis and Diagnostics.¿
The Board of Regents of the University of Texas System, of Austin, Texas, was awarded U.S. Patent No. 6,271,207 titled ¿Enhanced Expression of Transgenes.¿ The patent covers administration of chemotherapeutic drugs, radiation therapies or other agents that have a damaging effect on the DNA of cancer cells, to a cancer patient, followed by administration of gene therapy.
Variagenics Inc., of Cambridge, Mass., was issued U.S. Patent No. 6,291,175 titled ¿Methods for Treating A Neurological Disease by Determining BCHE Genotype.¿ The patent encompasses a method for genotyping the butyrylcholineserase gene to identify patients at risk for or diagnosed with Alzheimer¿s disease who are predisposed to respond to certain therapies.
Xenomics Inc., of San Francisco, was awarded U.S. Patent No. 6,287,820 titled ¿Methods for Detection of Nucleic Acid Sequences in Urine.¿ It covers diagnostic applications of urinary DNA analysis for the purpose of cancer detection and monitoring of cancer therapy.